Fountain Healthcare Partners

Fountain Healthcare Partners

Dublin-based Fountain Healthcare Partners was co-founded by Dr. Manus Rogan and Aidan King, who each spent roughly a decade at Elan Corporation before launching the firm. Rogan, a PhD chemist, moved through Elan's licensing and business development groups into its New York corporate venture arm, while King, a pharmacist and CFA charterholder, helped stand up that same Elan venture group after running strategic marketing for its drug delivery division. The duo returned to Ireland to build Fountain on a thesis that specialized life science knowledge — earned operating inside a biopharma company, not a generalist fund — could generate superior returns from the complex, regulated segment they knew best. The firm deploys capital from a series of funds that reached over €425 million across four vintages. Fountain targets seed and early-stage companies in specialty pharma, biopharmaceuticals, medical devices and diagnostics, spanning Europe and the United States. The team leads or co-leads syndicates and seeks paths to exit within three to six years. Portfolio evidence shows an emphasis on carving out assets from larger pharma pipelines and advancing them to large-cap acquirers: Fund 3 company Calypso Biotech, originally a Merck Serono spinout, was acquired by Novartis in January 2024 for up to $425 million, while Fund 2 investment KaNDy Therapeutics was sold to Bayer in 2020 for $425 million upfront. Earlier exits include Neuravi (to Johnson & Johnson, 2017), Civitas Therapeutics (to Acorda for $525 million, 2014), and Inflazome (to Roche for €380 million upfront, 2020). Active Fund 4 and Fund 3 positions include Exciva, Inotrem, Priothera, XyloCor Therapeutics, Corteria Pharmaceuticals, Dualyx, and Mainstay Medical. Fountain operates from offices in Dublin and New York with a lean team led by Rogan, King, and Partners Ena Prosser, Justin Lynch, and CFO Ruthanne Monaghan. In January 2026, portfolio company Vivasure Medical was acquired by Haemonetics for up to €185 million — a liquidity event that illustrates continued exit velocity from Fund 1-era assets. The firm has not publicly disclosed total headcount. Fountain's partnership draws on deep technical credentials: Prosser ran Enterprise Ireland's life sciences group before co-founding Fountain; Lynch founded his own medical device company between stints in corporate finance; Monaghan previously held senior finance roles at TVC Holdings and Hostelworld. The firm maintains a focused Responsible Investment Policy, though no separate philanthropic foundation is disclosed. Fountain's structural edge sits in its syndication posture and operating DNA. Nearly every partner carried an operating or venture seat at Elan before Fountain existed, giving the firm a repeatable pattern of sourcing preclinical and clinical-stage assets developed inside large pharma environments and positioning them for strategic exits. This is not a generalist venture platform applying life sciences as one vertical among many — the entire firm, from its deal leads to its financial controller, operates inside one sector. The team regularly leads or co-leads rounds, a risk-taking stance that distinguishes it from passive institutional life science LPs who rely solely on manager selection.